Reaction

Respiratory Tract Infection Viral reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,289 reports · 98 co-occurring drugs

As of the last recalculation, Respiratory Tract Infection Viral appears in 2,289 FAERS reports alongside 98 co-occurring drug terms. The strongest observed disproportionality signal is PALIVIZUMAB (PRR 34.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Palivizumab	57	34.6	34.7
Human Immunoglobulin G	53	23.9	23.9
Trimethoprim	26	20.3	20.3
Anti-Thymocyte Globulin (Rabbit)	16	18.2	18.2
Lumacaftor And Ivacaftor	16	17.1	17.1
Diphenhydramine Hydrochloride Capsule, Liquid Filled	39	16.9	16.9
Magnesium Sulfate In Water For	20	14.4	14.4
Magnesium Sulfate Heptahydrate	20	14.1	14.1
Magnesium Sulfate	20	14.1	14.1
Ixazomib	41	13.2	13.2
Vigabatrin	20	12.6	12.6
Thiotepa	13	12.4	12.5
Adrenalinum	54	12.1	12.1
Thiamine Hydrochloride	16	11.8	11.8
Valganciclovir Hydrochloride Powder,	15	11.2	11.3
Lidocaine	64	10.2	10.2
Zoledronic Acid	44	10.1	10.2
Lidicaine	53	10.1	10.1
Burn Relief	53	10.1	10.1
Diphenhydramine	68	10.1	10.1
Lidocaine Hydrochloride And Epinephrine	53	10.0	10.1
Lidocaine, Menthol	53	9.9	9.9
Tobramycin Solution	13	9.9	9.9
Fexofenadine Hcl	10	9.9	9.9
Tobramycin Sulfate	13	9.6	9.6
Teduglutide	14	9.5	9.5
Lidocaine Hydrochloride And Epinephrine Bitartrate	54	9.4	9.4
Epinephrine	65	9.3	9.3
Epoetin Alfa	12	9.3	9.3
Ivacaftor	8	9.2	9.2
Lidocaine 4%	53	9.0	9.0
Dornase Alfa	19	8.9	8.9
Amoxicillin And Clavulanate Potassium	26	8.8	8.8
Fludarabine Phosphate	37	8.7	8.7
Budesonide	55	8.7	8.7
Lidocaine Hydrochloride	56	8.6	8.6
Valacyclovir	39	8.6	8.6
Valganciclovir	17	8.3	8.3
Valganciclovir Hydrochloride	17	8.3	8.3
Infliximab-Dyyb	26	8.2	8.2
Cyclobenzaprine Hydrochloride	8	8.1	8.1
Filgrastim	33	8.1	8.1
Fluticasone Furoate	10	7.5	7.5
Sildenafil Powder,	29	7.5	7.5
Tiotropium Bromide Inhalation Spray	9	7.3	7.3
Bosentan	39	7.1	7.1
Fluticasone Propionate Nasal	23	7.0	7.0
Magnesium Oxide	31	6.8	6.8
Cannabidiol	17	6.6	6.7
Ado-Trastuzumab Emtansine	6	6.5	6.5
Valacyclovir Hydrochloride	48	6.3	6.3
Fluticasone Propionate And Salmeterol Xinafoate	40	6.1	6.1
Mepolizumab	33	6.1	6.1
Tobramycin	16	6.1	6.1
Cetirizine Hcl	6	6.0	6.0
Sildenafil	37	5.9	5.9
Elexacaftor, Tezacaftor, And Ivacaftor	8	5.8	5.9
Budesonide And Formoterol Fumarate Dihydrate	61	5.8	5.8
Posaconazole Delayed-Release	7	5.8	5.8
Daratumumab	25	5.7	5.7
Baricitinib	6	5.7	5.7
Montelukast	51	5.6	5.6
Piperacillin Sodium,Tazobactam Sodium	16	5.5	5.5
Asfotase Alfa	6	5.5	5.5
Riociguat	19	5.3	5.3
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	12	5.3	5.3
Naproxen Sodium, Pseudoephedrine Hydrochloride	12	5.3	5.3
Selinexor	5	5.3	5.3
Pegaspargase	7	5.2	5.2
Acyclovir	62	5.0	5.0
Obinutuzumab	9	5.0	5.0
Omalizumab	46	5.0	5.0
Treprostinil	64	4.7	4.7
Busulfan	8	4.6	4.6
Fexofenadine Hydrochloride	11	4.6	4.6
Carfilzomib	14	4.5	4.5
Pegvaliase-Pqpz	4	4.4	4.4
Sildenafil Citrate	59	4.3	4.3
Macitentan	32	4.2	4.2
Selexipag	12	4.2	4.2
Eculizumab	24	4.0	4.0
Nintedanib	13	3.8	3.8
Pomalidomide	42	3.8	3.8
Polatuzumab Vedotin	4	3.7	3.7
Azacitidine For	7	3.5	3.5
Blinatumomab	4	3.5	3.5
Budesonide, Glycopyrrolate, And Formoterol Fumarate	4	3.5	3.5
Ocrelizumab	23	3.4	3.4
Azacitidine	11	3.4	3.4
Ambrisentan	39	2.9	2.9
Atezolizumab	12	2.8	2.8
Axicabtagene Ciloleucel	3	2.8	2.8
Benralizumab	6	2.7	2.7
Lenalidomide	110	2.4	2.4
Lifitegrast	4	2.2	2.2
Bimekizumab	5	2.1	2.1
Pirfenidone	8	1.8	1.8
Dupilumab	76	1.4	1.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.